# Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

> **NCT02037477** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** Esomeprazole
- **DRUG:** Rabeprazole sodium

## Key facts

- **NCT ID:** NCT02037477
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02037477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02037477, "Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02037477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*